In line with the ability of γδ T cells to promote resistance to CDK4/6 inhibitors, the therapeutic activity of P+T against M/D-driven mammary tumors could be improved by: (1) a γδ TCR-antagonistic antibody, (2) an IL17A-neutralizing antibody, and (3) the deletion of Tcrd (which encodes one of the γδ TCR chains)10 from the host.7 Here, IL17A is linked to breast cancer.